EZH2 and nonpapillary renal cell carcinoma: Similar to the results obtained from the genetic manipulation, we found that pharmacologic inhibition by roscovitine, a pan inhibitor of CDK1, CDK2, and CDK5, or RO-3306, a CDK1-selective inhibitor (36, 37), not only abolished EZH2 T487 phosphorylation, but also decreased ZMYND8–EZH2 interaction at the endogenous level in 786-O ccRCC cells (Fig. 5I and SI Appendix, Fig. S4E).